ANN MATAKAS: Open Payments
NPI 1265793319 · ROSWELL, NM. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$634 in 37 payments from 10 companies in 2025. Trend: 2023 $547 · 2024 $934 · 2025 $634
Food & beverage: $634
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $222 |
| AstraZeneca Pharmaceuticals LP | 7 | $169 |
| Xeris Pharmaceuticals, Inc. | 3 | $63 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Novo Nordisk Inc | 2 | $38 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $24 |
| Dexcom, Inc. | 1 | $23 |
| Neurocrine BioSciences, Inc. | 1 | $20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $18 |
| GlaxoSmithKline, LLC. | 1 | $17 |
Products named: QULIPTA, AIRSUPRA, BREZTRI, GVOKE HYPOPEN, UBRELVY, REXULTI, VRAYLAR, Wegovy.
Industry payments across NM — which companies pay providers there.
